Alterity Therapeutics Ltd. Sponsored ADR Stock

$2.76

4.83% yesterday

Nasdaq, Apr 07, 10:00 pm CET

ISIN

US02155X1063

Symbol

ATHE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Alterity Therapeutics Ltd. Sponsored ADR Stock price

$2.76

-3.35 54.79% 5Y

Nasdaq, Closing price Mon, Apr 07 2025

-0.14 4.83%

ISIN

US02155X1063

Symbol

ATHE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$30.62m
Enterprise Value	$27.88m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	5.08
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-15.73m
Free Cash Flow (TTM) Free Cash Flow	$-10.89m
EPS (TTM) EPS	$-1.58
P/E forward	negative
P/S forward	10.23
EV/Sales forward	9.31
Short interest	0.51%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Alterity Therapeutics Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Alterity Therapeutics Ltd. Sponsored ADR forecast:

2x Buy

67%

1x Hold

33%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Alterity Therapeutics Ltd. Sponsored ADR forecast:

Buy

67%

Hold

33%

Analyst Estimates with Stock Price Targets

Financial data from Alterity Therapeutics Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.10 0.10	25% 25% -
Gross Profit	-0.10 -0.10	25% 25% -
- Selling and Administrative Expenses	3.68 3.68	30% 30% -
- Research and Development Expense	12 12	52% 52% -
EBITDA	-16 -16	46% 46% -
- Depreciation and Amortization	0.10 0.10	25% 25% -
EBIT (Operating Income) EBIT	-16 -16	46% 46% -
Net Profit	-13 -13	60% 60% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Alterity Therapeutics Ltd. Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

12 days ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc...

Neutral

GlobeNewsWire

●

about 2 months ago

Alterity Therapeutics Raises A$40.0 million in Placement

– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, Australia and SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease mo...

Neutral

GlobeNewsWire

●

2 months ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – – ATH434 Demonstrated a Favorable Safety Profile – – Webcast Held Yesterday with Access to the Recording Below – MELBOURNE, Australia and SA...

More Alterity Therapeutics Ltd. Sponsored ADR News

Company Profile

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Head office	Australia
CEO	David Stamler
Employees	10
Founded	1997
Website	www.alteritytherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now